McKesson Corporation

02/04/2026 | Press release | Distributed by Public on 02/04/2026 16:31

Quarterly Report for Quarter Ending December 31, 2025 (Form 10-Q)

Management's Discussion and Analysis of Financial Condition and Results of Operations.
INDEX TO MANAGEMENT'S DISCUSSION AND ANALYSIS
Section Page
General
38
Overview of our Business
38
Executive Summary
40
Trends and Uncertainties
40
Overview of Consolidated Results
41
Overview of Segment Results
45
New Accounting Pronouncements
49
Financial Condition, Liquidity, and Capital Resources
50
Cautionary Notice About Forward-Looking Statements
54
Available Information
54
GENERAL
Management's discussion and analysis of financial condition and results of operations, referred to as the "Financial Review," is intended to assist the reader in the understanding and assessment of significant changes and trends related to the results of operations and financial position of McKesson Corporation together with its subsidiaries (collectively, the "Company," "McKesson," "we," "our," or "us," and other similar pronouns). This discussion and analysis should be read in conjunction with the condensed consolidated financial statements and accompanying financial notes in Item 1 of Part I of this Quarterly Report on Form 10-Q ("Quarterly Report") and in Item 8 of Part II of our Annual Report on Form 10-K for the fiscal year ended March 31, 2025 previously filed with the Securities and Exchange Commission (the "SEC") on May 9, 2025 ("2025 Annual Report").
Our fiscal year begins on April 1 and ends on March 31. Unless otherwise noted, all references to a particular year refer to our fiscal year.
Certain statements in this report constitute forward-looking statements. See "Cautionary Notice About Forward-Looking Statements"included in this Quarterly Report.
Overview of our Business:
We are a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products, and services to help make quality care more accessible and affordable.
We implemented a new segment reporting structure commencing in the second quarter of fiscal 2026, which resulted in four reportable segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions ("RxTS"), and Medical-Surgical Solutions. Our Norwegian operations are included in Other. All prior segment information has been recast to reflect our new segment structure and current period presentation. Our organizational structure also includes Corporate, which consists of income and expenses associated with administrative functions and projects, as well as the results of certain investments. The factors for determining the reportable segments include the manner in which management evaluates the performance of the Company combined with the nature of individual business activities. We evaluate the performance of our operating segments on a number of measures, including revenues and operating profit before interest expense and income taxes.
MD&A Index
McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)
The following summarizes our four reportable segments. Refer to Financial Note 13, "Segments of Business,"to the accompanying condensed consolidated financial statements included in this Quarterly Report for further information regarding our reportable segments.
•North American Pharmaceuticalis a reportable segment that provides distribution and logistics services for branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs along with other healthcare-related products to wholesale and institutional customers in the United States ("U.S.") and Canada. In addition, the segment sells financial, operational, and clinical solutions to pharmacies (retail, hospital, alternate sites) and provides consulting, outsourcing, technological, and other services. The U.S. distribution operations was previously included in the former U.S. Pharmaceutical reportable segment and the Canadian operations was previously included in the former International reportable segment.
•Oncology & Multispecialtyis a reportable segment that includes provider solutions that encompass specialty drug distribution, group purchasing organizations, infusion services, direct to patient pharmacy capabilities, cell and gene therapy services with InspiroGene, technology solutions, practice consulting services, and vaccine distribution. In addition, the segment supports one of the largest networks of physician-led, integrated, community-based oncology practices dedicated to advancing high-quality, evidence-based cancer care in the U.S. The segment also includes PRISM Vision Holdings, LLC ("PRISM Vision"), which drives patient outcomes in a retina and ophthalmology setting. Combined with Sarah Cannon Research Institute and our technology business, Ontada, this segment provides research, insights, technologies, and services that address and improve cancer and specialty care. This segment was previously reflected in the former U.S. Pharmaceutical reportable segment.
•Prescription Technology Solutions is a reportable segment that combines automation and our ability to navigate the healthcare ecosystem to connect patients, pharmacies, providers, pharmacy benefit managers, health plans, and biopharma companies to address patients' medication access, affordability, and adherence challenges. RxTS offers technology services, which includes electronic prior authorization, prescription price transparency, benefit insight, dispensing support services, in addition to third-party logistics, and wholesale distribution support across various therapeutic categories and temperature ranges to biopharma customers throughout the product lifecycle.
•Medical-Surgical Solutionsis a reportable segment that provides medical-surgical supply distribution, logistics, and other services to healthcare providers, operating in ambulatory care environments, such as physician offices, surgery centers, and hospital reference labs, as well as extended care settings, including nursing homes and home health care agencies. This segment offers national brand medical-surgical products as well as McKesson's own line of high-quality products through a network of distribution centers within the U.S. On May 8th, 2025, we announced our intention to separate this segment into an independent company.
Our Norwegian operations, which provide distribution and services to wholesale and retail customers in Norway where we own, partner, or franchise with retail pharmacies, were previously included in the former International reportable segment, but are now included in Other. During the nine months ended December 31, 2025, we entered into a definitive agreement to sell our businesses in Norway, and classified the assets and liabilities as held for sale ("Norway disposal group"). On January 30, 2026, we completed the sale of our Norway disposal group. Refer to Financial Note 2, "Business Acquisitions and Divestitures,"to the accompanying condensed consolidated financial statements in this Quarterly Report for additional information.
Business Acquisitions and Divestitures
PRISM Vision Holdings, LLC
On April 1, 2025, we completed the acquisition of a controlling interest in PRISM Vision, a leading provider of general ophthalmology and retina administrative services. We acquired an 80% interest in PRISM Vision for $875 million in cash and prior owners, including management and physicians in PRISM Vision practices, retained a 20% ownership interest. As of the acquisition date, the financial results of PRISM Vision are reported within our Oncology & Multispecialty segment.
Community Oncology Revitalization Enterprise Ventures, LLC
On June 2, 2025, we completed the acquisition of a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC ("Core Ventures"), a business and administrative services organization established by Florida Cancer Specialists & Research Institute, LLC, ("FCS"). We acquired a 70% controlling interest in Core Ventures for $2.5 billion in cash and FCS physicians retained 30% interest. As of the acquisition date, Core Ventures is a part of the Oncology platform and financial results are reported within our Oncology & Multispecialty segment.
MD&A Index
McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)
Refer to Financial Note 2, "Business Acquisitions and Divestitures,"to the accompanying condensed consolidated financial statements in this Quarterly Report for additional information regarding these acquisition transactions.
Executive Summary:
The following summary provides highlights and key factors that impacted our business, operating results, financial condition, and liquidity for the three and nine months ended December 31, 2025:
•For the three months ended December 31, 2025 compared to the prior year, revenues increased by 11%, gross profit increased by 12%, total operating expenses were flat, and other income, net increased by 7%.
•For the nine months ended December 31, 2025 compared to the prior year, revenues increased by 15%, gross profit increased by 8%, total operating expenses decreased by 6%, and other income, net decreased by 14%. Refer to the "Overview of Consolidated Results" section below for an analysis of these changes;
•Diluted earnings per common share attributable to McKesson Corporation increased to $9.59 from $6.95 for the three months ended December 31, 2025 and increased to $24.73 from $15.80 for the nine months ended December 31, 2025 compared to the respective prior year periods;
•On April 1, 2025, we completed the acquisition of a controlling interest in PRISM Vision for $875 million in cash, as discussed in further detail in the "Business Acquisitions and Divestitures"section above;
•On June 2, 2025, we completed the acquisition of a controlling interest in Core Ventures for $2.5 billion in cash, as discussed in further detail in the "Business Acquisitions and Divestitures"section above;
•We recorded an immaterial net charge of $29 million for the nine months ended December 31, 2025 related to the bankruptcy of our customer, Rite Aid Corporation (including certain of its subsidiaries, "Rite Aid") as discussed further in the "Overview of Consolidated Results"section below;
•On May 8, 2025, we entered into a syndicated $1.0 billion 364-Day senior unsecured credit facility (the "364-Day Credit Facility") which is scheduled to mature in May 2026. Refer to Financial Note 8, "Debt and Financing Activities,"to the accompanying condensed consolidated financial statements in this Quarterly Report for additional information;
•On May 30, 2025, we completed a public debt offering of 4.65% Notes due May 30, 2030 in a principal amount of $650 million, 4.95% Notes due May 30, 2032 in a principal amount of $650 million, and 5.25% Notes due May 30, 2035 in a principal amount of $700 million, for total proceeds received, net of discounts and debt offering expenses, of $2.0 billion. The net proceeds from these notes in addition to cash on hand were utilized to fund the purchase of the interest in Core Ventures. Refer to Financial Note 8, "Debt and Financing Activities,"to the accompanying condensed consolidated financial statements in this Quarterly Report for additional information;
•On November 14, 2025, our €600 million outstanding principal amount of 1.50% Notes matured and were repaid using cash on hand;
•On December 3, 2025, our $500 million outstanding principal amount of 0.90% Notes matured and were repaid using cash on hand;
•During the nine months ended December 31, 2025, we returned $2.4 billion of cash to shareholders through $2.1 billion of common stock repurchases in open market transactions and $280 million of dividend payments. The total remaining authorization outstanding for repurchases of the Company's common stock at December 31, 2025 was $5.4 billion; and
•On July 29, 2025, our Board of Directors (the "Board") raised our quarterly dividend to $0.82 from $0.71 per share of common stock.
Trends and Uncertainties:
Government Policies
As described in "Item 1. Government Regulation" and "Item 1A - Risk Factors" in Part I of our 2025 Annual Report, our industry is highly regulated and is subject to risks and uncertainty caused by the volume and speed of changes to regulatory policies. Changes in regulatory posture and law may result in significant changes in healthcare policy, government funding of healthcare costs, and other laws affecting our operations, but the ultimate outcomes are difficult to predict.
MD&A Index
McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)
RESULTS OF OPERATIONS
Overview of Consolidated Results:
(Dollars in millions, except per share data) Three Months Ended December 31, Nine Months Ended December 31,
2025 2024 Change 2025 2024 Change
Revenues $ 106,158 $ 95,294 11 % $ 307,135 $ 268,228 15 %
Gross profit 3,685 3,284 12 10,506 9,684 8
Gross profit margin 3.47 % 3.45 % 2 bp 3.42 % 3.61 % (19) bp
Total operating expenses $ (2,066) $ (2,060) - % $ (6,444) $ (6,853) (6) %
Total operating expenses as a percentage of revenues 1.95 % 2.16 % (21) bp 2.10 % 2.55 % (45) bp
Other income, net $ 74 $ 69 7 % $ 200 $ 233 (14) %
Interest expense (63) (67) (6) (186) (220) (15)
Income before income taxes 1,630 1,226 33 4,076 2,844 43
Income tax expense (380) (298) 28 (832) (669) 24
Reported income tax rate 23.3 % 24.3 % (100) bp 20.4 % 23.5 % (310) bp
Net income 1,250 928 35 3,244 2,175 49
Net income attributable to noncontrolling interests (64) (49) 31 (164) (140) 17
Net income attributable to McKesson Corporation $ 1,186 $ 879 35 % $ 3,080 $ 2,035 51 %
Diluted earnings per common share attributable to McKesson Corporation $ 9.59 $ 6.95 38 % $ 24.73 $ 15.80 57 %
Weighted-average diluted common shares outstanding 123.7 126.6 (2) % 124.5 128.8 (3) %
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
bp - basis point
Revenues
Revenues increased for the three and nine months ended December 31, 2025 compared to the same prior year periods, primarily due to market growth in our North American Pharmaceutical segment, including higher volumes largely from retail national account customers. Market growth includes growing drug utilization and newly launched products, partially offset by branded to generic drug conversion. Revenues for the three and nine months ended December 31, 2025 was also favorably impacted by growth in our Oncology & Multispecialty segment primarily due to higher specialty pharmaceutical sales.
Gross Profit
Gross profit increased for the three and nine months ended December 31, 2025 compared to the same prior year periods primarily due to growth in our Oncology & Multispecialty segment, driven by the addition of providers in practice management and growth of specialty pharmaceuticals, and in our Prescription Technology Solutions segment, driven by higher volumes.
We recognized gains of $15 million and $31 million for the three months ended December 31, 2025 and 2024, respectively, and $23 million and $184 million for the nine months ended December 31, 2025 and 2024, respectively, related to our share of antitrust legal settlements. We recognized these amounts within "Cost of sales" in the Condensed Consolidated Statements of Operations within our North American Pharmaceutical segment.
MD&A Index
McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)
Gross profit for the nine months ended December 31, 2024 was impacted by restructuring charges of $63 million related to a broad set of initiatives to drive operational efficiencies and increase cost optimization efforts as discussed in Financial Note 3, "Restructuring, Impairment, and Related Charges, Net,"to the accompanying condensed consolidated financial statements included in this Quarterly Report. We recorded this amount related to impairment of inventories within "Cost of sales" in the Condensed Consolidated Statements of Operations within our North American Pharmaceutical segment.
A last-in, first out ("LIFO") credit of $10 million and a charge of $89 million were recognized during the three months ended December 31, 2025 and 2024, respectively, and a credit of $28 million and a charge of $85 million were recognized during the nine months ended December 31, 2025 and 2024, respectively, primarily due to lower expected brand inflation in the current fiscal year.
Our North American Pharmaceutical business uses the LIFO method of accounting for the majority of its inventories, which results in cost of sales that more closely reflects replacement cost than under other accounting methods. The business' practice is to pass on to customers published price changes from suppliers. Manufacturers generally provide us with price protection, which limits price related inventory losses. A LIFO charge is recognized when the net effect of price increases on pharmaceutical and non-pharmaceutical products held in inventory exceeds the impact of price declines, including the effect of branded pharmaceutical products that have lost market exclusivity. A LIFO credit is recognized when the net effect of price declines exceeds the impact of price increases on pharmaceutical and non-pharmaceutical products held in inventory. Our quarterly LIFO adjustment is based on our estimates of the annual LIFO adjustment which is impacted by expected changes in year-end inventory quantities, product mix, and manufacturer pricing practices, which may be influenced by market and other external factors. Changes to any of the above factors could have a material impact to our annual LIFO adjustment. The actual valuation of inventory under the LIFO method is calculated at the end of the fiscal year.
Total Operating Expenses
A summary of the components of our total operating expenses for the three and nine months ended December 31, 2025 and 2024 is as follows:
•Selling, distribution, general, and administrative expenses ("SDG&A"):consists of personnel costs, transportation costs, depreciation and amortization, lease costs, professional fee expenses, administrative expenses, provision for bad debts and related recoveries, remeasurement charges to fair value less costs to sell, and other general charges.
•Claims and litigation charges, net:These charges include adjustments for estimated probable settlements related to our controlled substance monitoring and reporting, and opioid-related claims, as well as any applicable income items or credit adjustments due to subsequent changes in estimates. Legal fees to defend claims, which are expensed as incurred, are included within SDG&A.
•Restructuring, impairment, and related charges, net:Charges recorded under this component include those incurred for programs in which we change our operations, the scope of a business undertaken by our business units, or the manner in which that business is conducted, as well as long-lived asset impairments.
Three Months Ended December 31, Nine Months Ended December 31,
(Dollars in millions) 2025 2024 Change 2025 2024 Change
Selling, distribution, general, and administrative expenses $ 2,030 $ 2,028 - % $ 6,300 $ 6,532 (4) %
Claims and litigation charges, net - - - (2) 108 (102)
Restructuring, impairment, and related charges, net 36 32 13 146 213 (31)
Total operating expenses $ 2,066 $ 2,060 - % $ 6,444 $ 6,853 (6) %
Percent of revenues 1.95 % 2.16 % (21) bp 2.10 % 2.55 % (45) bp
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
bp - basis point
For the three months ended December 31, 2025, total operating expenses increased and total operating expenses as a percentage of revenues decreased compared to the same prior year period. For the nine months ended December 31, 2025, total
MD&A Index
McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)
operating expenses and total operating expenses as a percentage of revenues decreased compared to the same prior year period. Total operating expenses were impacted by the following significant items:
•SDG&A for the nine months ended December 31, 2025 includes an immaterial net charge of $29 million which primarily reflects the provision for bad debts partially offset by the disposition of rebate liabilities and vendors credits related to the bankruptcy of Rite Aid;
•SDG&A for the nine months ended December 31, 2024 includes charges of $666 million to remeasure the sale of our Rexall and Well.ca businesses in Canada ("Canadian retail disposal group") to fair value less costs to sell. The remeasurement adjustment includes a $48 million loss related to the accumulated other comprehensive loss balances associated with this disposal. Of the total charges recorded during the period, $604 million were included within our North American Pharmaceutical segment and $62 million were included within Corporate expenses, net;
•SDG&A for the nine months ended December 31, 2025 was impacted by lower operating expenses from the completed divestiture of our Canadian retail disposal group in fiscal 2025, as discussed in more detail in Financial Note 2, "Business Acquisitions and Divestitures,"to the accompanying condensed consolidated financial statements in this Quarterly Report;
•SDG&A for the nine months ended December 31, 2025 was impacted by higher operating expenses related to the acquisitions completed during fiscal 2026, as discussed in more detail in Financial Note 2, "Business Acquisitions and Divestitures,"to the accompanying condensed consolidated financial statements in this Quarterly Report;
•Claims and litigation charges, net primarily consists of a charge of $108 million for the nine months ended December 31, 2024 related to our estimated liability for opioid-related claims as discussed in more detail in Financial Note 11, "Commitments and Contingent Liabilities,"to the accompanying condensed consolidated financial statements included in this Quarterly Report; and
•Restructuring, impairment, and related charges, net were $36 million and $32 million for the three months ended December 31, 2025 and 2024, respectively, and $146 million and $213 million for the nine months ended December 31, 2025 and 2024, respectively, as discussed below under "Restructuring Initiatives."
Goodwill Impairment
We evaluate goodwill for impairment on an annual basis in the first fiscal quarter, and at an interim date if indicators of potential impairment exist. The annual impairment testing performed in fiscal 2026 and fiscal 2025 did not indicate any impairment of goodwill, and no goodwill impairment charges were recorded during the three and nine months ended December 31, 2025 and 2024. However, other risks, expenses, and future developments, such as government actions, increased regulatory uncertainty, and material changes in key market assumptions limit our ability to estimate projected cash flows, which could adversely affect the fair value of various reporting units in future periods.
For additional disclosure of our policy regarding goodwill, refer to the "Critical Accounting Estimates" section within Item 7 - Management's Discussion and Analysis of Financial Condition and Results of Operations in Part II of our 2025 Annual Report.
Restructuring Initiatives
We recorded restructuring, impairment, and related charges of $36 million and $32 million for the three months ended December 31, 2025 and 2024, respectively, and $146 million and $213 million for the nine months ended December 31, 2025 and 2024, respectively. These charges were included in "Restructuring, impairment, and related charges, net" in the Condensed Consolidated Statements of Operations.
MD&A Index
McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)
During the second quarter of fiscal 2025, we approved enterprise-wide initiatives to modernize and accelerate our technology service operating model, which were intended to improve business continuity, compliance, operating efficiency and advance investments to streamline the organization. These initiatives include cost reduction efforts and support other rationalization efforts within Corporate, and the Medical-Surgical Solutions and North American Pharmaceutical segments to help realize long-term sustainable growth. We anticipate total charges related to these initiatives of $650 million to $700 million, consisting primarily of employee severance and other employee-related costs as well as facility, exit, and other related costs, including long-lived asset impairments. These programs are anticipated to be substantially complete in fiscal 2028. We recorded charges of $26 million and $116 million for the three and nine months ended December 31, 2025, respectively, and $18 million and $245 million for the three and nine months ended December 31, 2024, respectively, related to these initiatives, which primarily includes severance and other employee-related costs as well as facility exit and other related costs, including long-lived asset impairments and a $63 million for the nine months ended December 31, 2024 related to inventory impairments recorded within "Cost of sales" in the Condensed Consolidated Statements of Operations.
Refer to Financial Note 3, "Restructuring, Impairment, and Related Charges, Net,"to the accompanying condensed consolidated financial statements included in this Quarterly Report for further information on our restructuring initiatives.
Other Income, Net
Other income, net for the three and nine months ended December 31, 2025 compared to the same prior year periods was impacted by net gains from certain investments in equity securities and a favorable impact from interest income. Other income, net for the nine months ended December 31, 2025 compared to the same prior year period was impacted by a prior year net gain of $101 million related to our investments in equity securities of certain U.S. growth stage companies in the healthcare industry, partially offset by a prior year loss of $43 million related to one of our equity method investments.
Interest Expense
Interest expense decreased for the three and nine months ended December 31, 2025 compared to the same prior year periods primarily due to changes in our derivative portfolio in fiscal 2026 and increased capitalized interest from higher capital spending, partially offset by interest from increased average balances of the Company's loan portfolio in fiscal 2026. Interest expense may fluctuate based on timing, amounts, and interest rates of term debt repaid and new term debt issued, as well as amounts incurred associated with financing fees. Refer to Financial Note 8, "Debt and Financing Activities,"to the accompanying condensed consolidated financial statements included in this Quarterly Report for more information.
Income Tax Expense
For the three months ended December 31, 2025 and 2024, we recorded income tax expense of $380 million and $298 million, respectively. For the nine months ended December 31, 2025 and 2024, we recorded income tax expense of $832 million and $669 million, respectively. Our income tax rates were 23.3% and 24.3% for the three months ended December 31, 2025 and 2024, respectively, and 20.4% and 23.5% for the nine months ended December 31, 2025 and 2024, respectively.
Fluctuations in our reported income tax rates are primarily due to changes in our business mix of earnings among various taxing jurisdictions and discrete tax items recognized in the quarters. Refer to Financial Note 4, "Income Taxes,"to the accompanying condensed consolidated financial statements included in this Quarterly Report for more information.
Net Income Attributable to Noncontrolling Interests
Net income attributable to noncontrolling interests for the three and nine months ended December 31, 2025 and 2024 primarily represents the proportionate results of third-party equity interests in ClarusONE Sourcing Services LLP, Vantage Oncology Holdings, LLC, and SCRI Oncology, LLC.
MD&A Index
McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)
Noncontrolling interests with redemption features, such as put rights, that are not solely within our control are considered redeemable noncontrolling interests. During the nine months ended December 31, 2025, we initially recognized redeemable noncontrolling interests of $700 million and $25 million related to our acquisitions of Core Ventures and PRISM Vision, respectively. We utilize a Monte Carlo simulation model to determine the fair value of the redeemable noncontrolling interests on a quarterly basis. As a result of the quarterly valuation process, we recorded an adjustment to the redemption value of the redeemable noncontrolling interests of an immaterial amount and $25 million for the three months ended December 31, 2025 for PRISM Vision and Core Ventures, respectively, and $2 million and $70 million for the nine months ended December 31, 2025 for PRISM Vision and Core Ventures, respectively. Redeemable noncontrolling interests are presented outside of stockholders' deficit in our Condensed Consolidated Balance Sheet. Refer to the "Selected Measures of Liquidity and Capital Resources" section of this Financial Review and Financial Note 5, "Redeemable Noncontrolling Interests and Noncontrolling Interests,"to the accompanying condensed consolidated financial statements included in this Quarterly Report for more information on changes to our redeemable and noncontrolling interests during the first nine months of fiscal 2026.
Net Income Attributable to McKesson Corporation
Net income attributable to McKesson Corporation was $1.2 billion and $879 million for the three months ended December 31, 2025 and 2024, respectively, and $3.1 billion and $2.0 billion for the nine months ended December 31, 2025 and 2024, respectively. Diluted earnings per common share attributable to McKesson Corporation was $9.59 and $6.95 for the three months ended December 31, 2025 and 2024, respectively, and $24.73 and $15.80 for the nine months ended December 31, 2025 and 2024, respectively. Our diluted earnings per share includes the cumulative effects of share repurchases during each period.
Weighted-Average Diluted Common Shares Outstanding
Diluted earnings per common share was calculated based on a weighted-average number of shares outstanding of 123.7 million and 126.6 million for the three months ended December 31, 2025 and 2024, respectively, and 124.5 million and 128.8 million for the nine months ended December 31, 2025 and 2024, respectively. Weighted-average diluted shares outstanding for the three and nine months ended December 31, 2025 decreased from the same prior year periods primarily due to the cumulative effect of share repurchases, as discussed in the "Share Repurchases Plans" section of this Financial Review.
Overview of Segment Results:
Segment Revenues:
Three Months Ended December 31, Nine Months Ended December 31,
(Dollars in millions) 2025 2024 Change 2025 2024 Change
Segment revenues
North American Pharmaceutical $ 88,322 $ 81,198 9 % $ 257,532 $ 227,564 13 %
Oncology & Multispecialty 13,010 9,493 37 35,712 27,431 30
Prescription Technology Solutions 1,500 1,371 9 4,310 3,877 11
Medical-Surgical Solutions 2,991 2,949 1 8,639 8,527 1
Other 335 283 18 942 829 14
Total revenues $ 106,158 $ 95,294 11 % $ 307,135 $ 268,228 15 %
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
North American Pharmaceutical
Three Months Ended December 31, 2025 vs. 2024
North American Pharmaceutical revenues for the three months ended December 31, 2025 increased $7.1 billion or 9% compared to the same prior year period. Within the segment, sales to U.S. pharmacies and healthcare providers increased $7.0 billion primarily due to higher volumes from retail national account customers, partially offset by branded to generic drug conversions.
MD&A Index
McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)
Nine Months Ended December 31, 2025 vs. 2024
North American Pharmaceutical revenues for the nine months ended December 31, 2025 increased $30.0 billion or 13% compared to the same prior year period. Within the segment, sales to U.S. pharmacies and healthcare providers increased $29.8 billion primarily due to higher volumes from retail national account customers, partially offset by branded to generic drug conversions.
Oncology & Multispecialty
Three Months Ended December 31, 2025 vs. 2024
Oncology & Multispecialty revenues for the three months ended December 31, 2025 increased $3.5 billion or 37% compared to the same prior year period primarily driven by growth in provider solutions due to the addition of providers within practice management and higher specialty pharmaceutical sales.
Nine Months Ended December 31, 2025 vs. 2024
Oncology & Multispecialty revenues for the nine months ended December 31, 2025 increased $8.3 billion or 30% compared to the same prior year period primarily driven by growth in provider solutions due to the addition of providers within practice management and higher specialty pharmaceutical sales.
Prescription Technology Solutions
Three Months Ended December 31, 2025 vs. 2024
RxTS revenues for the three months ended December 31, 2025 increased $129 million or 9% compared to the same prior year period due to increased volumes from our third-party logistics and higher technology services revenues.
Nine Months Ended December 31, 2025 vs. 2024
RxTS revenues for the nine months ended December 31, 2025 increased $433 million or 11% compared to the same prior year period due to increased volumes from our third-party logistics and higher technology services revenues.
Medical-Surgical Solutions
Three Months Ended December 31, 2025 vs. 2024
Medical-Surgical Solutions revenues for the three months ended December 31, 2025 increased $42 million or 1% compared to the same prior year period. Within the segment, sales to ambulatory care customers increased $27 million driven by underlying business growth and sales to extended care customers increased by $18 million. These increases were partially offset by other sales which decreased by $3 million.
Nine Months Ended December 31, 2025 vs. 2024
Medical-Surgical Solutions revenues for the nine months ended December 31, 2025 increased $112 million or 1% compared to the same prior year period. Within the segment, sales to ambulatory care customers increased $93 million driven by underlying business growth, other sales increased by $15 million, and sales to extended care customers increased by $4 million.
MD&A Index
McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)
Other Segment Expense, Segment Operating Profit and Corporate Expenses, Net:
Three Months Ended December 31, Nine Months Ended December 31,
(Dollars in millions) 2025 2024 Change 2025 2024 Change
Other segment expense, net (1)
North American Pharmaceutical (2)
$ 87,267 $ 80,454 8 % $ 255,031 $ 225,771 13 %
Oncology & Multispecialty (3)
12,706 9,291 37 34,864 26,881 30
Prescription Technology Solutions 1,239 1,152 8 3,552 3,250 9
Medical-Surgical Solutions (4)
2,726 2,680 2 7,933 7,975 (1)
Other 304 269 13 870 785 11
Total other segment expense, net $ 104,242 $ 93,846 11 % $ 302,250 $ 264,662 14 %
Segment operating profit
North American Pharmaceutical $ 1,055 $ 744 42 % $ 2,501 $ 1,793 39 %
Oncology & Multispecialty 304 202 50 848 550 54
Prescription Technology Solutions 261 219 19 758 627 21
Medical-Surgical Solutions 265 269 (1) 706 552 28
Other 31 14 121 72 44 64
Subtotal 1,916 1,448 32 4,885 3,566 37
Corporate expenses, net (5)
(223) (155) 44 (623) (502) 24
Interest expense (63) (67) (6) (186) (220) (15)
Income before income taxes $ 1,630 $ 1,226 33 % $ 4,076 $ 2,844 43 %
Segment operating profit margin
North American Pharmaceutical 1.19 % 0.92 % 27 bp 0.97 % 0.79 % 18 bp
Oncology & Multispecialty 2.34 2.13 21 2.37 2.01 36
Prescription Technology Solutions 17.40 15.97 143 17.59 16.17 142
Medical-Surgical Solutions 8.86 9.12 (26) 8.17 6.47 170
Other 9.25 4.95 430 7.64 5.31 233
Any percentage changes displayed above which are not meaningful are displayed as zero percent.
bp - basis point
(1)Other segment expense, net includes cost of sales, total operating expenses, as well as other income, net, for our reportable segments.
(2)Other segment expense, net for our North American Pharmaceutical segment includes the following:
•related to the bankruptcy of our customer Rite Aid, we recorded an immaterial net charge of $29 million during the nine months ended December 31, 2025, which primarily reflects the provision for bad debts partially offset by the disposition of rebate liabilities and vendors credits;
•cash receipts for our share of antitrust legal settlements were $15 million and $31 million for the three months ended December 31, 2025 and 2024, respectively, and $23 million and $184 million for the nine months ended December 31, 2025 and 2024, respectively;
•a credit of $10 million and a charge of $89 million related to the LIFO method of accounting for inventories for the three months ended December 31, 2025 and 2024, respectively, and a credit of $28 million and a charge of $85 million for the nine months ended December 31, 2025 and 2024, respectively;
•a charge of $604 million for the nine months ended December 31, 2024 to remeasure the assets and liabilities of the Canadian retail disposal group to fair value less costs to sell, as discussed in Financial Note 2, "Business Acquisitions and Divestitures,"to the accompanying condensed consolidated financial statements included in this Quarterly Report;
•restructuring charges of $67 million for the nine months ended December 31, 2024 for restructuring initiatives as discussed in Financial Note 3, "Restructuring, Impairment, and Related Charges, Net,"to the accompanying condensed consolidated financial statements included in this Quarterly Report; and
MD&A Index
McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)
•a charge of $57 million for the nine months ended December 31, 2024 related to our estimated liability for opioid-related claims as discussed in Financial Note 11, "Commitments and Contingent Liabilities,"to the accompanying condensed consolidated financial statements included in this Quarterly Report.
(3)Other segment expense, net for our Oncology & Multispecialty segment includes the following:
•a net gain of $51 million for the nine months ended December 31, 2025 related to the sale of an investment and market decisions; and
•a loss of $43 million for the nine months ended December 31, 2024 related to one of the Company's equity method investments.
(4)Other segment expense, net for our Medical-Surgical Solutions segment for the nine months ended December 31, 2024 includes restructuring charges of $169 million related to a broad set of initiatives to drive operational efficiencies and increase cost optimization efforts as discussed in Financial Note 3, "Restructuring, Impairment, and Related Charges, Net,"to the accompanying condensed consolidated financial statements included in this Quarterly Report.
(5)Corporate expenses, net includes the following:
•a charge of $62 million for the nine months ended December 31, 2024 related to the effect of accumulated other comprehensive loss components from our Canadian retail disposal group, as discussed in Financial Note 2, "Business Acquisitions and Divestitures,"to the accompanying condensed consolidated financial statements included in this Quarterly Report;
•a net gain of $101 million for the nine months ended December 31, 2024 related to our investments in equity securities of certain U.S. growth stage companies in the healthcare industry, as discussed in Financial Note 10, "Fair Value Measurements,"to the accompanying condensed consolidated financial statements included in this Quarterly Report;
•a net charge of $51 million for the nine months ended December 31, 2024 related to our estimated liability for opioid-related claims as discussed in Financial Note 11, "Commitments and Contingent Liabilities,"to the accompanying condensed consolidated financial statements included in this Quarterly Report; and
•restructuring charges of $38 million and $10 million for the three months ended December 31, 2025 and 2024, respectively, and charges of $105 million and $34 million for the nine months ended December 31, 2025 and 2024, respectively, for restructuring initiatives as discussed in Financial Note 3, "Restructuring, Impairment, and Related Charges, Net,"to the accompanying condensed consolidated financial statements included in this Quarterly Report.
North American Pharmaceutical
Three Months Ended December 31, 2025 vs. 2024
Operating profit for this segment increased for the three months ended December 31, 2025 compared to the same prior year period largely due to the disposition of rebate liabilities and vendors credits related to the bankruptcy of Rite Aid, higher pharmaceutical distribution volumes across the segment, and a LIFO credit in the current year compared to a charge in fiscal 2025, partially offset by an increase in operating expenses to support higher volumes and a decrease from net cash proceeds received representing our share of antitrust legal settlements.
Nine Months Ended December 31, 2025 vs. 2024
Operating profit for this segment increased for the nine months ended December 31, 2025 compared to the same prior year period primarily due to prior year remeasurement charges related to our Canadian retail disposal group held for sale, as discussed in Financial Note 2, "Business Acquisitions and Divestitures"to the accompanying condensed consolidated financial statements included in this Quarterly Report, higher pharmaceutical distribution volumes across the segment, a LIFO credit in the current year compared to a charge in fiscal 2025, and a prior year charge of $57 million related to our estimated liability for opioid-related claims. These increases are partially offset by the impact of the bankruptcy of Rite Aid, a decrease from net cash proceeds received representing our share of antitrust legal settlements, and an increase in operating expenses to support higher volumes.
Oncology & Multispecialty
Three Months Ended December 31, 2025 vs. 2024
Operating profit for this segment increased for the three months ended December 31, 2025 compared to the same prior year period primarily due to growth in specialty pharmaceuticals, partially offset by an increase in operating expenses to support higher volumes.
MD&A Index
McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)
Nine Months Ended December 31, 2025 vs. 2024
Operating profit for this segment increased for the nine months ended December 31, 2025 compared to the same prior year period primarily due to growth in specialty pharmaceuticals, a net gain of $51 million related to the sale of an investment and market decisions, and a prior year loss of $43 million related to one of our equity method investments, partially offset by an increase in operating expenses to support higher volumes.
Prescription Technology Solutions
Three Months Ended December 31, 2025 vs. 2024
Operating profit for this segment increased for the three months ended December 31, 2025 compared to the same prior year period driven by increased volumes primarily from growth in our technology services.
Nine Months Ended December 31, 2025 vs. 2024
Operating profit for this segment increased for the nine months ended December 31, 2025 compared to the same prior year period driven by increased volumes primarily from growth in our technology services.
Medical-Surgical Solutions
Three Months Ended December 31, 2025 vs. 2024
Operating profit for this segment decreased for the three months ended December 31, 2025 compared to the same prior year period primarily due to a decline in the contribution from our ambulatory care and extended care businesses, partially offset by higher restructuring charges in fiscal 2025.
Nine Months Ended December 31, 2025 vs. 2024
Operating profit for this segment increased for the nine months ended December 31, 2025 compared to the same prior year period primarily due to higher restructuring charges in fiscal 2025 and lower expenses resulting from business rationalization initiatives, partially offset by a decline in the contribution from our ambulatory care and extended care businesses.
Corporate Expenses, Net
Three Months Ended December 31, 2025 vs. 2024
Corporate expenses, net increased for the three months ended December 31, 2025 compared to the same prior year period primarily due to higher restructuring charges in fiscal 2026, partially offset by prior year remeasurement charges related to our Canadian retail disposal group held for sale, as discussed in Financial Note 2, "Business Acquisitions and Divestitures"to the accompanying condensed consolidated financial statements included in this Quarterly Report.
Nine Months Ended December 31, 2025
Corporate expenses, net increased for the nine months ended December 31, 2025 compared to the same prior year period primarily due to higher restructuring charges in fiscal 2026 and prior year gains related to our investments in equity securities of certain U.S. growth stage companies in the healthcare industry, partially offset by lower litigation charges in the current year compared to prior year and prior year remeasurement charges related to our Canadian retail disposal group held for sale, as discussed in Financial Note 2, "Business Acquisitions and Divestitures"to the accompanying condensed consolidated financial statements included in this Quarterly Report.
New Accounting Pronouncements
New accounting pronouncements that we have recently adopted as well as those that have been recently issued but not yet adopted by us are included in Financial Note 1, "Significant Accounting Policies,"to the accompanying condensed consolidated financial statements included in this Quarterly Report.
MD&A Index
McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)
FINANCIAL CONDITION, LIQUIDITY, AND CAPITAL RESOURCES
We expect our available cash generated from operations and our short-term investment portfolio, together with our existing sources of liquidity from our credit facilities, commercial paper program, and other borrowings will be sufficient to fund our short-term and long-term capital expenditures, working capital, and other cash requirements. We remain adequately capitalized, including access to liquidity from our $4.0 billion revolving credit facility and $1.0 billion 364-day credit facility. At December 31, 2025, we were in compliance with all debt covenants, and believe we have the ability to continue to meet our debt covenants in the future.
The following table summarizes the net change in cash, cash equivalents, and restricted cash for the periods shown:
Nine Months Ended December 31,
(Dollars in millions) 2025 2024 Change
Net cash provided by (used in):
Operating activities $ 2,734 $ (1,663) $ 4,397
Investing activities (3,857) (509) (3,348)
Financing activities (1,811) (1,110) (701)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash 31 (21) 52
Net change in cash, cash equivalents, and restricted cash $ (2,903) $ (3,303) $ 400
Operating Activities
Operating activities provided cash of $2.7 billion and used cash of $1.7 billion during the nine months ended December 31, 2025 and 2024, respectively. Cash flows from operations can be significantly impacted by factors such as the timing of receipts from customers, inventory receipts, and payments to vendors. Additionally, working capital is primarily a function of sales and purchase volumes, inventory requirements, and vendor payment terms.
For the nine months ended December 31, 2025, net cash provided by operating activities increased by $4.4 billion compared to the same prior year period. This increase was primarily due to the following:
•the Company's net income increased by $1.1 billion and was impacted by lower net non-cash items of $708 million, compared to the same prior year period driven by factors discussed in more detail in the "Overview of Consolidated Results"section of this Financial Review;
•an increase in cash of $2.2 billion related to accounts payable as a result of customary vendor payment scheduling and timing related to the day of the week on which the period ends, partially offset by a decrease in cash of $1.0 billion due to higher inventory requirements during the period compared to the prior year;
•an increase in net cash of $1.9 billion related to accounts receivable is primarily due to favorable timing of collections in the current period and timing related to the day of the week on which the period ends; and
•an increase in cash from other assets and liabilities primarily related to lower contract liability payments.
Investing Activities
Investing activities used cash of $3.9 billion and $509 million during the nine months ended December 31, 2025 and 2024, respectively. Investing activities for the nine months ended December 31, 2025 includes $3.4 billion of net cash payments for acquisitions, including $2.5 billion and $875 million for the acquisitions of the interests in Core Ventures and PRISM Vision, respectively, as discussed in further detail in Financial Note 2, "Business Acquisitions and Divestitures,"to the accompanying condensed consolidated financial statements in this Quarterly Report. Investing activities for the nine months ended December 31, 2025 and 2024 includes $560 million and $581 million, respectively, in capital expenditures for property, plant, and equipment and capitalized software. Investing activities for the nine months ended December 31, 2025 were also impacted by the receipt of proceeds of $137 million related to the sale of businesses and investments, as discussed in Financial Note 10, "Fair Value Measurements,"to the accompanying condensed consolidated financial statements included in this Quarterly Report.
MD&A Index
McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)
Investing activities for the nine months ended December 31, 2024 were also impacted by the receipt of proceeds of $92 million related to the sale of equity securities, as discussed in Financial Note 10, "Fair Value Measurements,"to the accompanying condensed consolidated financial statements included in this Quarterly Report.
Financing Activities
Financing activities used cash of $1.8 billion and of $1.1 billion during the nine months ended December 31, 2025 and 2024, respectively, which includes $2.1 billion and $2.8 billion of cash paid for share repurchases, respectively, as well as $280 million and $254 million of cash paid for dividends, respectively. Financing activities also includes cash receipts of $2.3 billion and $11.4 billion, and cash payments of $2.3 billion and $9.0 billion for the nine months ended December 31, 2025 and 2024, respectively, related to short-term borrowings of commercial paper.
On May 30, 2025, we completed a public debt offering of 4.65% Notes due May 30, 2030 in a principal amount of $650 million, 4.95% Notes due May 30, 2032 in a principal amount of $650 million, and 5.25% Notes due May 30, 2035 in a principal amount of $700 million, for total proceeds received, net of discounts and debt offering expenses, of $2.0 billion. The net proceeds from these notes were utilized to fund the purchase of our interest in Core Ventures.
On November 14, 2025, our €600 million outstanding principal amount of 1.50% Notes matured and on December 3, 2025, our $500 million outstanding principal amount of 0.90% Notes matured, and were repaid using cash on hand. Refer to Financial Note 8, "Debt and Financing Activities,"to the accompanying condensed consolidated financial statements in this Quarterly Report for additional information.
On September 10, 2024, we completed a public offering of 4.25% Notes due September 15, 2029 in a principal amount of $500 million. Proceeds received from this note issuance, net of discounts and offering expenses, were approximately $496 million. We utilized the net proceeds from this note issuance along with cash on hand to redeem our $500 million outstanding principal amount of 5.25% Notes due February 15, 2026 prior to maturity at a redemption price equal to 100% of the principal amount plus accrued and unpaid interest through the settlement date.
Cash used for other financing activities generally includes the cash value of shares surrendered for tax withholding and payments to noncontrolling interests.
Share Repurchase Plans
The Board has authorized the repurchase of common stock. We may repurchase common stock from time-to-time through open market transactions, privately negotiated transactions, accelerated share repurchase programs, or by combinations of such methods, any of which may use pre-arranged trading plans that are designed to meet the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934 ("Exchange Act"). The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including our stock price, corporate and regulatory requirements, tax implications, restrictions under our debt obligations, other uses for capital, impacts on the value of remaining shares, cash generated from operations, and market and economic conditions.
Excise taxes of $7 million were accrued for shares repurchased during the three months ended December 31, 2025 and 2024, respectively. Excise taxes of $17 million and $23 million were accrued for shares repurchased during the nine months ended December 31, 2025 and 2024, respectively. On July 30, 2025, we made a payment of $26 million for fiscal 2025 excise taxes previously accrued. As of December 31, 2025 and March 31, 2025, the amount accrued for excise taxes was $17 million and $26 million within "Other accrued liabilities" in our Condensed Consolidated Balance Sheets, respectively.
MD&A Index
McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)
Information regarding share repurchase activity for the nine months ended December 31, 2025 and 2024 was as follows:
Share Repurchases (1)
(In millions, except price per share)
Total
Number of
Shares
Purchased (2)
Average Price
Paid Per Share(3)
Approximate
Dollar Value of
Shares that May
Yet Be Purchased
Under the
Programs
Balance at March 31, 2025 $ 7,469
Q1 Shares repurchased - Open market
0.8 $ 709.84 (590)
Q2 Shares repurchased - Open market 1.2 693.25 (809)
Q3 Shares repurchased - Open market (4)
0.8 831.33 (689)
Balance at December 31, 2025 $ 5,381
(1)This table does not include the value of equity awards surrendered to satisfy tax withholding obligations or forfeitures of equity awards.
(2)The number of shares purchased reflects rounding adjustments.
(3)The average price paid per share includes $17 million of excise taxes for the nine months ended December 31, 2025.
(4)Of the total dollar value, $9 million was accrued within "Other accrued liabilities" in the Company's Condensed Consolidated Balance Sheet as of December 31, 2025 for share repurchases that were executed in late December 2025 and settled in early January 2026.
Share Repurchases (1)
(In millions, except price per share)
Total
Number of
Shares
Purchased (2)
Average Price
Paid Per Share(3)
Approximate
Dollar Value of
Shares that May
Yet Be Purchased
Under the
Programs
Balance at March 31, 2024 $ 6,615
Q1 Shares repurchased - Open market 1.0 $ 548.20 (527)
July 2024 Board Authorization
4,000
Q2 Shares repurchased - Open market
2.9 $ 533.46 (1,528)
Q3 Shares repurchased - Open market(4)
1.5 $ 537.48 $ (821)
Balance at December 31, 2024 $ 7,739
(1)This table does not include the value of equity awards surrendered to satisfy tax withholding obligations or forfeitures of equity awards.
(2)The number of shares purchased reflects rounding adjustments.
(3)The average price paid per share includes $23 million of excise taxes for the nine months ended December 31, 2024.
(4)Of the total dollar value, $8 million was accrued within "Other accrued liabilities" in our Condensed Consolidated Balance Sheet as of December 31, 2024 for share repurchases that were executed in late December 2024 and settled in early January 2025.
MD&A Index
McKESSON CORPORATION
FINANCIAL REVIEW (CONTINUED)
(UNAUDITED)
Selected Measures of Liquidity and Capital Resources
(Dollars in millions) December 31, 2025 March 31, 2025
Cash, cash equivalents, and restricted cash $ 3,053 $ 5,956
Working capital (8,434) (6,206)
Debt to capital ratio (1)
106.4 % 125.3 %
(1)This ratio describes the relationship and changes within our capital resources, and is computed as the sum of total debt divided by the sum of total debt and McKesson stockholders' deficit, which excludes noncontrolling interests and accumulated other comprehensive loss.
Cash equivalents, which are readily convertible to known amounts of cash, are carried at fair value. Cash equivalents are primarily invested in AAA-rated U.S. government money market funds, short-term deposits with financial institutions, and short-term commercial papers issued by non-financial institutions. Deposits with financial institutions are primarily denominated in U.S. dollars and the functional currencies of our foreign subsidiaries, including Canadian dollars. Deposits could exceed the amounts insured by the Federal Deposit Insurance Corporation in the U.S. and similar deposit insurance programs in other jurisdictions. We mitigate the risk of our short-term investment portfolio by depositing funds with reputable financial institutions and monitoring risk profiles and investment strategies of money market funds.
Our cash and cash equivalents balance as of December 31, 2025 and March 31, 2025 included approximately $1.2 billion and $2.9 billion, respectively, of cash held by our subsidiaries outside of the U.S. Our primary intent is to utilize this cash for foreign operations for an indefinite period of time. Although the majority of cash held outside the U.S. is available for repatriation, doing so could subject us to foreign withholding taxes and state income taxes. We may remit foreign earnings to the U.S. to the extent it is tax efficient to do so. We do not anticipate the tax impact from remitting these earnings to be material. Following enactment of the 2017 Tax Cuts and Jobs Act, the repatriation of cash to the U.S. is generally no longer taxable for federal income tax purposes.
Working capital primarily includes cash and cash equivalents, receivables, inventories, and prepaid expenses, net of drafts and accounts payable, short-term borrowings, current portion of long-term debt, current portion of operating lease liabilities, and other accrued liabilities. Our businesses require substantial investments in working capital that are susceptible to large variations during the year as a result of inventory purchase patterns and seasonal demands. Inventory purchase activity is a function of sales activity and other requirements.
Consolidated working capital decreased at December 31, 2025 compared to March 31, 2025 primarily due to an increase in drafts and accounts payable from increased purchasing driven by increased sales and timing, a decrease in cash and cash equivalents, and an increase in other accrued liabilities. These were partially offset by an increase in inventories, net, and receivables, net, driven by higher sales and timing, and a decrease in the current portion of long term debt.
Our debt to capital ratio decreased for the nine months ended December 31, 2025 due to net income attributable to McKesson for fiscal 2026 and issuance of new long-term debt, partially offset by share repurchases and dividend payments as well as repayment of long-term debt upon maturity.
On July 29, 2025, we raised our quarterly dividend from $0.71 to $0.82 per share of common stock. We anticipate that we will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remain within the discretion of the Board and will depend upon our future earnings, financial condition, capital requirements, legal requirements, and other factors.
Redeemable Noncontrolling Interests
During the nine months ended December 31, 2025, we initially recognized redeemable noncontrolling interests of $25 million and $700 million related to our acquisition of 80% of PRISM Vision and 70% of Core Ventures, respectively. The balance of redeemable noncontrolling interests is reported at the greater of its carrying value or its maximum redemption value at each reporting date. The 30% minority interest retained by FCS is classified as redeemable noncontrolling interest, with a put option exercisable every five years, subject to a floor of 75% of initial fair value. We utilize a Monte Carlo simulation model to determine the fair value of the redeemable noncontrolling interests on a quarterly basis. As a result of the quarterly valuation process, we recorded an adjustment to the redemption value of the redeemable noncontrolling interests of an immaterial amount
MD&A Index
McKESSON CORPORATION
FINANCIAL REVIEW (CONCLUDED)
(UNAUDITED)
and $25 million for the three months ended December 31, 2025 for PRISM Vision and Core Ventures, respectively, and $2 million and $70 million for the nine months ended December 31, 2025 for PRISM Vision and Core Ventures, respectively. Refer to Financial Note 5, "Redeemable Noncontrolling Interests and Noncontrolling Interests,"to the accompanying condensed consolidated financial statements included in this Quarterly Report for additional information on redeemable noncontrolling interests.
Capital Resources
We fund our working capital requirements primarily with cash and cash equivalents, proceeds from short-term borrowings from our commercial paper issuances, and longer-term credit agreements and debt offerings. Funds necessary for future debt maturities and our other cash requirements, including any future payments that may be made related to our total estimated litigation liability of $5.7 billion as of December 31, 2025 payable under the terms of various settlement agreements for opioid-related claims, are expected to be met by existing cash balances, cash flow from operations, existing credit sources, and future borrowings. Long-term debt markets and commercial paper markets, our primary sources of capital after cash flow from operations, are open and accessible to us should we decide to access those markets. Detailed information regarding our debt and financing activities is included in Financial Note 8, "Debt and Financing Activities,"to the accompanying condensed consolidated financial statements included in this Quarterly Report.
We believe that our future operating cash flow, financial assets, and access to capital and credit markets, including our credit facilities, give us the ability to meet our financing needs for the foreseeable future. However, there can be no assurance that an increase in volatility or disruption in the global capital and credit markets will not impair our liquidity or increase our costs of borrowing.
CAUTIONARY NOTICE ABOUT FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q, including "Management's Discussion and Analysis of Financial Condition and Results of Operations" in Item 2 of Part I of this report, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Exchange Act. Forward-looking statements may be identified by their use of terminology such as "believes," "expects," "anticipates," "may," "will," "should," "seeks," "approximately," "intends," "projects," "plans," "estimates," "targets," or the negative of these words or other comparable terminology. The discussion of proposed acquisition or disposition transactions, financial trends, strategy, plans, assumptions, expectations, litigation outcomes, or intentions may also include forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected, anticipated, or implied. Although it is not possible to predict or identify all such risks and uncertainties, they include, but are not limited to, the factors discussed in the "Risk Factors" section in Item 1A of Part I of the 2025 Annual Report and in our publicly available SEC filings and press releases. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date such statements were first made. Except to the extent required by federal securities laws, we undertake no obligation to publicly release the result of any revisions to any forward-looking statements to reflect events or circumstances after the date the statements are made, or to reflect the occurrence of unanticipated events.
AVAILABLE INFORMATION
We routinely post on our company website, and via our social media channels, information that may be material to investors, including details and updates to information disclosed elsewhere, which may include business developments, earnings and financial performance, sustainability matters, details regarding upcoming events, and materials for presentations to investors and financial analysts. Investors are encouraged to monitor our website www.mckesson.com. Interested parties can sign up on our website, including our Investor Relations site, to receive automated e-mail alerts, such as via RSS newsfeed, when we post certain information. Interested parties can also follow our social media feed @McKesson on X. The content on any website or social media channel is not incorporated by reference into this report, unless expressly noted otherwise.
McKesson Corporation published this content on February 04, 2026, and is solely responsible for the information contained herein. Distributed via EDGAR on February 04, 2026 at 22:31 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]